DrugPatentWatch Database Preview

Details for Patent: 9,242,986

« Back to Dashboard

Which drugs does patent 9,242,986 protect, and when does it expire?

Patent 9,242,986 protects JULUCA, TIVICAY, and TRIUMEQ, and is included in three NDAs.

This patent has twenty-six patent family members in thirteen countries.

Summary for Patent: 9,242,986

Title:	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Abstract:	A synthesis approach providing an early ring attachment via a bromination to compound 1-1 yielding compound II-II, whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q. ##STR00001##
Inventor(s):	Kawasuji; Takashi (Osaka, JP), Nagamatsu; Daiki (Osaka, JP)
Assignee:	SHIONOGI & CO., LTD. (Osaka, JP) ViiV Healthcare Company (Research Triangle Park, NC)
Application Number:	14/272,823
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,242,986
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 9,242,986

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017		RX	Yes	Yes			Y	Y
Viiv Hlthcare	TIVICAY	dolutegravir sodium	TABLET;ORAL	204790-002	Jun 9, 2016		RX	Yes	No			Y	Y
Viiv Hlthcare	TIVICAY	dolutegravir sodium	TABLET;ORAL	204790-003	Jun 9, 2016		RX	Yes	No			Y	Y
Viiv Hlthcare	TIVICAY	dolutegravir sodium	TABLET;ORAL	204790-001	Aug 12, 2013		RX	Yes	Yes			Y	Y

Non-Orange Book US Patents Family Members for Patent 9,242,986

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,365,587	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
8,624,023	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
8,754,214	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates

International Family Members for US Patent 9,242,986

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009325128
Brazil	PI0923217
Canada	2744019
Canada	2955957